 Ionis stock tumbled Friday after partner AstraZeneca decided against sending their high cholesterol treatment into Phase 3 testing. The post Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test appeared first on Investors Business Daily. 